Prohost Letter #381
QUARTERLY FINANCIAL RESULTS IN THE BIOTECH SECTOR

Investors Concerns, Excitement and Expectations (Part 3)

For the past quarter of a century we spent focusing on the biotech sector, observing it from all angles and weighing the possible outcomes of its individual member companies. We conclude that: Regardless of what the firms quarterly financial results might point to success or failure, the market will in most quatrers give the good, the bad and the ugly, equal failing (F) grades. So, we prepared ourselves to see biotech stock prices plummet four times a year and . . .